联系方式:400-990-3999 / 邮箱:sales@xiyashiji.com
西亚试剂 —— 品质可靠,值得信赖
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
Saravana M. Dhanasekaran O Alejandro Balbin Guoan Chen Ernest Nadal Shanker Kalyana-Sundaram Jincheng Pan Brendan Veeneman Xuhong Cao Rohit Malik Pankaj Vats Rui Wang Stephanie Huang Jinjie Zhong Xiaojun Jing Matthew Iyer Yi-Mi Wu Paul W. Harms Jules Lin Rishindra Reddy Christine Brennan Nallasivam Palanisamy Andrew C. Chang Anna Truini Mauro Truini Dan R. Robinson David G. Beer Arul M. Chinnaiyan
Lung cancer is emerging as a paradigm for disease molecular subtyping, facilitating targeted therapy based on driving somatic alterations. Here we perform transcriptome analysis of 153 samples representing lung adenocarcinomas, squamous cell carcinomas, large cell lung cancer, adenoid cystic carcinomas and cell lines. By integrating our data with The Cancer Genome Atlas and published sources, we analyse 753 lung cancer samples for gene fusions and other transcriptomic alterations. We show that higher numbers of gene fusions is an independent prognostic factor for poor survival in lung cancer. Our analysis confirms the recently reported ?CD74-?NRG1 fusion and suggests that ?NRG1, ?NF1 and Hippo pathway fusions may play important roles in tumours without known driver mutations. In addition, we observe exon-skipping events in ?c-MET, which are attributable to splice site mutations. These classes of genetic aberrations may play a significant role in the genesis of lung cancers lacking known driver mutations.